Sector News

Novo Nordisk to smarten up its disposable insulin pens with digital diabetes devicemaker Biocorp

October 3, 2021
Life sciences

To make it easier for people with diabetes to track their insulin doses, Novo Nordisk has inked a deal with devicemaker Biocorp to smarten up its line of mass-produced, disposable insulin pens.

Biocorp’s Mallya digital device clips directly onto prefilled insulin injectors and logs delivery amounts and times by linking to a smartphone via Bluetooth. The French company has already been tapped by Roche to connect pens to its diabetes care platform to help share patients’ treatment information with their healthcare providers.

The new deal with Novo Nordisk provides for the reusable Mallya’s eventual distribution after a new version has been proven to work with the company’s FlexTouch insulin pen.

FlexTouch—which carries most of Novo Nordisk’s insulins and will serve as a platform for all new insulins going forward—features a unique, push-button dosing mechanism that required a redesign of the current Mallya device, which previously received a CE mark for use in Europe.

In a statement, Biocorp CEO Éric Dessertenne described the project as a huge recognition of Mallya’s potential, with Novo Nordisk providing almost half of the insulin used worldwide while distributing more than 500 million insulin pens to 30 million users in 2020 alone.

Biocorp is set to receive an upfront payment as well as milestone funding tied to the new device’s development. The exact amounts were not disclosed, but the companies expect to be able to ramp up production starting in 2022.

Earlier this month, Biocorp announced a deal to expand Mallya’s scope, working with Germany’s Merck KGaA to develop a specific version to help monitor injections of human growth hormone among children and teenagers with certain hormone deficiencies.

Over the first half of this year, Biocorp posted an operating loss of about 1.3 million euros, or about $1.5 million U.S., with revenues of 3.8 million euros being outpaced by 5.2 million euros in operating expenses.

Dessertenne said, “the prolonged COVID-19 crisis and Big Pharma’s priority choices have clearly slowed patients’ adoption of Mallya,” and added that its commercial alliances with Roche—as well as a digital insulin pen partnership with Sanofi, launched in late 2019—have had only marginal impacts so far, with their full effects expected to come next year.

by Conor Hale


comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach